In IL-27-containing groups, several inflammation or infection-related pathways were predicted to be activated, including TREM1 signaling, pattern recognition receptors, neuroinflammation, and acute phase response, whereas inhibition of the PD1/PD-L1 cancer immunotherapy pathway was predicted. The gene discussed is CD274; the disease is cancer.